I haven't voted yet and will wait until after the upcoming conference next week.
Misinformation and half truths unfortunately from both sides filled with facts which support their side.
I'm still leaning toward AMRN (white vote).
What I really want is a compromise of 2 to 3 seats on the board.
I truly feel that shareholder representation has been dismally missing from day one with Amarin and the connection between our board and the common shareholder is/was nonexistent until they (Amarin) were "forced" by Denner to play.
Alot of this could have been avoided had we been more proactive in discussions with Sarissa. That's not to say that Sarissa was an angel and played fair either with not responding until right before the general meeting and then demanding their candidates placed(bully tactic). Like I said, no one is an angel in this scenario and if we think one side is all good and the other side is all bad we are" fooling yourself if you don't believe it." Styx (to take a theme from the latest Sarissa presentation).
Now we are out another $7 million which pretty much was our earnings for Q2.
I'm still on the Amarin side because I see things finally developing. UK roll out appears to be going even bettter than I expected with uptake on formularies. We've cut spending significantly. We should have Spain on our side by end of May at the latest IMO and from my research (very similar tactics as in UK but not near as visible what is happening behind the scenes). China approval by 1st Q (my prediction is by end of this month).
I see Italy and Netherlands by end of Q3 at the latest but no France until Q1 2024.
We have our FDC moving forward which I am afraid that Sarissa may stop in a cost saving measure since that is more down the road that in the next 1 to 1 1/2 year plan that I see them having.
I see Sarissa settling with the countries for lower pricing of V as well. Not a bad strategy if trying to determine a value for AMRN if MA is the priority.
I don't blame anyone for voting Blue. It's been a butt kicking journey and many are sick and tired and ready for the journey to work toward a sale to begin.
I'm looking at it as if the median has been 37% on those companies they have had seats that ain't terrible but the Medicines company will skew that number quite a bit and I want a whole lot higher than 37% from where we stand when they win their 7 seats.
I will take 5.75-7.75 with Sarissa and it sure beats 1.25/share but I would much rather hang in there another year or two past the Sarissa sale for 12-15/best case scenario. Anything in the 8-10 range and I'm a happy camper. Main thing is has Amarin woken up that the retail investor means something and our shareholders need a voice.
Amarin BOD need to buy some shares from their own pocket and show everyone that they have faith in the company too. If they win or can settle, they need to put at least 2 directors on the board and not forget what could have happened.
If this board is a representation of the voting of the general shareholder mindset though, Sarissa is getting 7 of the 15 seats.
As a side note, timing is everything. I bought roughly 13,000 shares for my mother at the end of Dec and she is already up over 85% on her investment.
Not so much for me but the significant shares I bought in Q 4 around 1.18-1.21 have certainly performed well. Who knows the future.
Best of luck to all but right now I'm still White card to be transparent to the board.
